• PTX3–TLR4/NF-κB/FGF21 Axis in ONFH

  2026-08-14

  This study identifies a protective PTX3–TLR4/NF-κB/FGF21 signaling axis in glucocorticoid-induced osteonecrosis of the femoral head. Genetic loss-of-function, recombinant PTX3 treatment, pathway blockade, and downstream rescue experiments support PTX3 as a mechanistically defined regulator of osteogenesis, apoptosis, and femoral-head bone preservation.

• Pexidartinib (PLX3397) TAM Research Workflow

  2026-08-13

  Build reproducible macrophage-focused assays with Pexidartinib (PLX3397), from DMSO stock preparation through CSF1R target-engagement and tumor-microenvironment readouts. The workflow also distinguishes broad CSF1R-axis modulation from SPP1-specific phenotypic control, helping researchers select more informative endpoints.

• Hypoxia and Immunometabolism in Tumor Microenvironment

  2026-08-13

  This review integrates tumor hypoxia, metabolic competition, and immune-cell dysfunction into a unified model of immunosuppressive tumor microenvironment formation. Its practical value lies in linking oxygen and nutrient constraints to therapeutic opportunities while clarifying why metabolic and redox measurements should be interpreted within their cellular and spatial context.

• Targeted SPP1 Inhibition Reprograms Tumor Myeloid Cells

  2026-08-12

  The reference study developed a macrophage phenotypic screen and a TAM-avid nanocarrier strategy to reduce SPP1 expression rather than relying on conventional macrophage polarization markers. Its lead compound, CANDI460, lowered SPP1 in vitro and in vivo and produced tumor remissions in several murine models, providing a framework for targeted tumor microenvironment macrophage modulation.

• EdU Imaging Kits (488) for S-Phase Analysis

  2026-08-12

  EdU Imaging Kits (488) use 5-ethynyl-2'-deoxyuridine and click chemistry to label newly synthesized DNA. The K1175 kit supports fluorescence microscopy and flow cytometry while avoiding the harsh DNA denaturation required by many BrdU workflows.

• ω-Agatoxin IVA in Epileptogenesis: Rat Study Insights

  2026-08-11

  The reference study links Cav2.1 channel inhibition with delayed seizure onset, reduced epileptogenesis, increased BDNF, and lower cleaved caspase-3 expression in a rat chemical-kindling model. Its combined EEG, behavioral, and immunohistochemical design provides a useful framework for evaluating P/Q-type calcium channel blockade beyond acute seizure suppression.

• D-Luciferin (potassium salt): Reliable Assays

  2026-08-11

  A scenario-based guide to using D-Luciferin (potassium salt), SKU C3654, for luciferase reporter assays, ATP measurements, and in vivo bioluminescence imaging. It explains substrate chemistry, aqueous preparation, controls, signal interpretation, and practical product-selection criteria for reproducible laboratory workflows.

• Hydrocortisone in Radiation-Response Assays

  2026-08-10

  Hydrocortisone is more than a glucocorticoid hormone reference standard: it can define cellular stress context in radiation and inflammation experiments. This article translates a breast cancer RNA-mechanism study into practical assay-design principles while addressing handling, controls, and model limitations.

• Atrial Natriuretic Peptide: Research Workflows

  2026-08-09

  Build reproducible ANP assays for vascular, renal, and adipose models with practical guidance on reconstitution, exposure design, controls, and troubleshooting. A separate neuroimmune reference study provides a useful causal-experiment framework while underscoring why adiponectin and Atrial Natriuretic Peptide should not be treated as interchangeable reagents.

• KG-501 in Macrophage–Tumor Signaling Studies

  2026-08-08

  KG-501 is a CREB–coactivator interaction inhibitor that can help dissect transcriptional control in macrophage–tumor models. This article connects its molecular pharmacology with the TLR4-dependent colitis-associated colorectal cancer study while emphasizing assay design, interpretation, and translational limitations.

• Autophagy and Resveratrol-Induced Apoptosis in RCC

  2026-08-07

  Yao, Fan, and He show that resveratrol induces ROS-associated mitochondrial apoptosis and caspase-3 activation in renal cell carcinoma 786-O cells, while simultaneously stimulating JNK-linked autophagy. Their results identify autophagy as a protective response, suggesting that combining resveratrol with autophagy inhibition may intensify tumor-cell death, although validation beyond this in vitro model is required.

• Substrate Stiffness Directs Dentinogenesis via LAMB1–FAK–MEK

  2026-08-07

  This study demonstrates that substrate stiffness modulates odontoblast-like cell differentiation and mineralization through the LAMB1–FAK–MEK1/2 signaling pathway. The findings establish a mechanistic link between biomechanical cues and dentinogenesis, offering new perspectives for dental tissue engineering.

• BI 2536 and PLK1: New Strategies for Mitotic Checkpoint Targ

  2026-08-06

  Explore how BI 2536, a next-generation PLK1 inhibitor from APExBIO, is reshaping translational cancer research. This thought-leadership article integrates mechanistic discoveries—such as the regulation of p31comet-mediated mitotic checkpoint disassembly—with strategic guidance for leveraging BI 2536 in in vitro and in vivo oncology models. We bridge foundational biology, robust experimental protocols, and future-facing outlooks to provide a roadmap for researchers seeking to advance the field of mitotic control and apoptosis induction in cancer cells.

• Benzyl Quinolone Carboxylic Acid: Optimizing M1 Receptor Res

  2026-08-06

  Benzyl Quinolone Carboxylic Acid (BQCA) empowers researchers to dissect and modulate M1 muscarinic acetylcholine receptor signaling with unmatched selectivity and reproducibility. Leveraging new insights into GRK-mediated bias, BQCA enables advanced cognitive and Alzheimer's disease research workflows, translating molecular discoveries into actionable, reliable protocols.

• Merbromin as a Selective Mixed-Type Inhibitor of SARS-CoV-2

  2026-08-05

  This study identifies Merbromin as a potent, selective mixed-type inhibitor of the SARS-CoV-2 main protease (3CLpro) through high-throughput in vitro screening. The findings provide a new chemical scaffold for antiviral drug design and highlight the importance of precise protease targeting in COVID-19 research.

553 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page